BeiGene, Ltd. (NASDAQ:BGNE) Insider Sells $7,804,944.00 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) insider Xiaodong Wang sold 41,760 shares of the stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $186.90, for a total value of $7,804,944.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Xiaodong Wang also recently made the following trade(s):

• On Tuesday, November 26th, Xiaodong Wang sold 40,468 shares of BeiGene stock. The stock was sold at an average price of $190.10, for a total transaction of $7,692,966.80.

BeiGene Stock Down 0.5 %

Shares of NASDAQ BGNE opened at $179.35 on Friday. The business has a 50-day moving average price of $207.23 and a 200 day moving average price of $186.89. The stock has a market cap of $17.47 billion, a PE ratio of -21.77 and a beta of 0.57. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05. BeiGene, Ltd. has a 52-week low of $126.97 and a 52-week high of $248.16.

BeiGene (NASDAQ:BGNE) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $1 billion during the quarter, compared to analyst estimates of $983.26 million. BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. BeiGene’s revenue was up 28.2% compared to the same quarter last year. During the same period in the previous year, the company posted $2.01 earnings per share. Equities research analysts forecast that BeiGene, Ltd. will post -5.64 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new stake in shares of BeiGene during the third quarter worth about $1,614,000. Quantinno Capital Management LP acquired a new stake in BeiGene during the 3rd quarter worth approximately $295,000. Point72 Asset Management L.P. grew its stake in shares of BeiGene by 74.9% in the 3rd quarter. Point72 Asset Management L.P. now owns 667,166 shares of the company’s stock valued at $149,785,000 after purchasing an additional 285,784 shares during the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of BeiGene in the third quarter valued at approximately $67,000. Finally, Erste Asset Management GmbH purchased a new stake in shares of BeiGene during the third quarter worth approximately $4,478,000. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Morgan Stanley reiterated an “overweight” rating and set a $300.00 price target on shares of BeiGene in a report on Tuesday, December 3rd. JPMorgan Chase & Co. increased their target price on BeiGene from $200.00 to $235.00 and gave the company an “overweight” rating in a report on Tuesday, October 22nd. TD Cowen lifted their price target on BeiGene from $254.00 to $260.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. JMP Securities initiated coverage on BeiGene in a research report on Wednesday, September 18th. They set a “market outperform” rating and a $288.00 price objective for the company. Finally, StockNews.com lowered BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $253.69.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.